MP18-20 THE NANOKNIFE ELECTROPORATION ABLATION TRIAL (NEAT): A PROSPECTIVE DEVELOPMENT STUDY

effects of combined “TURP+HIFU” for local radical ablation of high risk Prostate Cancer (hrPCa). METHODS: 480 hrPCa patients (T3-4 or initial PSA u003e20 or Gleason 8-10, N0, M0) were treated with TURP and consecutive transrectal complete HIFU Ablation with Ablatherm Integrated Imaging (EDAP-TMS, Lyon-France) and followed prospectively up to 17 years. “Disease progression” (failure) was defined as: Last PSAu003einitial PSA (PSAi) or M +/or onset of Salvage Therapy. RESULTS: In a high risk PCa patient cohort with a median follow up of 7 years (0.6-17.8) over all survival was 71.7%, metastasis free survival 91%, cancer specific survival 92.9% and progression free survival 63%. 30% needed adjuvant salvage ADT and 7% other salvage therapies in follow up after median 1.5 (0.1-12.5) years. Therapy induced side effects were: Stress Incontinence 7.9%, Obstruction: 3.7%, Fistula/Osteitis os pubis: 1.5%; UTI: 21.4%. CONCLUSIONS: Local radical prostate cancer ablation through transurethral resection (TURP) and transrectal complete High Intensity Focused Ultrasound (HIFU) with Ablatherm integrated imaging is a valid therapy even in high risk prostate cancer patients.